The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 12, 2019

Filed:

Mar. 29, 2012
Applicants:

Ningshu Liu, Berlin, DE;

Claudia Schneider, Berlin, DE;

Inventors:

Ningshu Liu, Berlin, DE;

Claudia Schneider, Berlin, DE;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/436 (2006.01); A61K 31/5377 (2006.01); C07D 487/04 (2006.01); A61K 31/517 (2006.01); A61K 45/06 (2006.01); A61K 31/635 (2006.01); C12Q 1/6886 (2018.01); G01N 33/574 (2006.01);
U.S. Cl.
CPC ...
C07D 487/04 (2013.01); A61K 31/436 (2013.01); A61K 31/517 (2013.01); A61K 31/5377 (2013.01); A61K 31/635 (2013.01); A61K 45/06 (2013.01); C12Q 1/6886 (2013.01); G01N 33/57415 (2013.01);
Abstract

The present invention relates to: —use of a 2,3-dihydroimidazo[1,2-c]quinazoline compound, or of a pharmaceutical composition containing same, as a sole active agent, or of a combination of a) said compound or a pharmaceutical composition containing said compound and b) one or more further active agents, for the preparation of a medicament for the treatment or prophylaxis of cancer; —combinations of a) said compound and b) one or more further active agents; —a pharmaceutical composition comprising said compound as a sole active agent for the treatment of breast cancer; —a pharmaceutical composition comprising a combination of a) said compound and b) one or more further active agents; —use of biomarkers involved in the modification of Bel expression, HER family expression and/or activation, PIK3CA signaling and/or loss of PTEN for predicting the sensitivity and/or resistance of a cancer patient to said compound and providing a rationale-based synergistic combination as defined herein to increase sensitivity and/or to overcome resistance; and —a method of determining the level of a component of one or more of Bcl expression, HER family expression and/or activation, PIK3CA signaling and/or loss of PTEN.


Find Patent Forward Citations

Loading…